eHealth Ventures

FIZE Medical Inc. is a manufacturer of medical devices that specialize in measuring urine output, essential for managing critically ill patients. Founded in 2014 and based in Modi'in-Maccabim-Re'ut, Israel, the company offers a technology that automates urine measurement, facilitating real-time monitoring and integrating seamlessly with healthcare information technology platforms. This innovation allows healthcare providers to detect early indicators of kidney function deterioration, enabling timely adjustments to therapy and ultimately improving patient outcomes in intensive care settings. FIZE Medical is dedicated to enhancing fluid management in ICUs through its advanced, AI-powered solutions.

DreaMed Diabetes, Ltd. is a medical device and software-as-a-service company focused on diabetes treatment and management. Founded in 2014 and based in Israel, the company is known for its innovative solutions, including Glucositter, a closed-loop insulin delivery system that monitors glucose levels in real-time and adjusts insulin delivery accordingly. DreaMed Diabetes has made significant advancements in decision support tools for diabetes management and was the first company to receive FDA clearance for a decision support system that utilizes data from continuous glucose monitors and insulin pumps. Its Advisor Pro software, developed by diabetes professionals, leverages artificial intelligence to enable healthcare providers to quickly analyze patient data and determine optimal treatment plans. This system aims to improve patient outcomes by facilitating frequent titration changes and enhancing online monitoring, ultimately helping to lower A1C levels and reduce the risk of complications. DreaMed Diabetes emphasizes patient-centered care, ensuring that all individuals receive high-quality treatment regardless of their circumstances.

AccuLine is a digital healthcare company focused on preventing heart attacks by offering innovative solutions for early detection of coronary artery disease (CAD). The company is developing CORA, a non-invasive examination technology that provides a smart, accurate, and user-friendly alternative to traditional stress tests. By streamlining the detection process, CORA enables healthcare providers to identify CAD more swiftly and cost-effectively, ultimately aiming to save millions of lives worldwide through timely intervention.

Nitur is developing COPatch, a flexible patch equipped with ultrasound micro-transducers that can be easily and quickly placed on a patient’s chest. It provides continuous and accurate hemodynamic data. The ultrasound signals are processed by an AI machine in order to provide an accurate continuous cardiac output parameters.​

Insight Axis uses EEG Analytics proposes to create an algorithm-based platform for predicting the compliance and responsiveness of neuropsychiatric patients to different medications. The platform will enable physicians to predict the patient’s neurobiological response to specific medications before treatment has even begun. The platform will create patient-specific brainwave signatures using data from EEG results. Using this Brain Signature, the algorithm will be able to calculate neuro-markers in the brain and then categorically assess the potential of drug suitability for the individual patient.

Acute Otitis Media (AOM) causes poor conductance of the Chorda Tympani nerve, resulting in its functional impairment, interpreted by the brain as impaired taste sensation. During the inflammation period of AOM, there is a difference in the taste sensation at the two sides of the tongue. While the unaffected side transmits normal taste sensation, on the affected side there is decrease in taste transmission and sensation. The taste buds can be activated with electrical stimulation and the gustatory evoked potentials (GEPs) can be recorded at the cortical gustatory cortex using EEG. Given the observation that AOM is usually unilateral and that the taste sensation on the side of the infection is damaged, electrical stimulation of both sides of the tongue should resulted in different GEPs reading from the infected side compared to the intact side, detecting the presence of AOM. Talma Medical develops a breakthrough innovative technology for accurate clinical diagnostic at home. An over the counter, easy to use and mostly accurate device will make a revolution in the way AOM is diagnosed.

TuneMe is a virtual assistance software that combines artificial intelligence and voice analysis to craft customized treatments incorporating innovative vibroacoustic neuro-stimulation. Using unique technology to rebalance the autonomic nervous system, TuneMe offers a multi-platform neurostimulation solution, specifically designed for individuals experiencing PTSD and sleep difficulties. ​

Wizermed provides a remedy for migraine relief. The technology empowers migraine sufferers to prepare and take preventive steps based on AI-based migraine attack forecasts by constantly monitoring data from the user's smartwatch sensors.

ToDX product is an at home diagnostic platform that will perform tests with comparable accuracy to PCR results. The first clinical application of this at-home diagnostic platform will be applied to STI’s (sexually transmitted infections), including chlamydia, gonorrhea, and trichomoniasis. ToDX plans to widen the clinical applications to the respiratory infections, including diagnosis of papillomavirus strains and the diagnosis of upper respiratory virus strains.

Startest is developing an easy-to-use test to detect blood glucose levels in prediabetic patients. The test is designed to be for one-time use and is compatible with an online platform. The test has the same precision as a regular glucose meter, but is administered through Smartest’s patent needle mechanism, which is less painful to patients than traditional blood glucose testing.

IdentifAI Genetics revolutionizes the way prenatal testing is done.

Olive Diagnostics has developed an innovative passive urine analysis sensor that can be mounted on any toilet, enabling continuous health monitoring through urinalysis. This sensor utilizes a combination of spectroscopy and artificial intelligence to analyze the urine stream and provide real-time health alerts to users. By uploading data to a cloud-based platform, Olive Diagnostics facilitates ongoing biomarker tracking for various health indicators such as hydration, alcohol levels, pregnancy, and ovulation. This technology not only empowers individuals to gain insights into their health and body functions but also offers pharmaceutical and clinical research organizations a reliable method to monitor drug compliance and usage. By making urine lab services accessible at home, Olive Diagnostics aims to enhance disease detection and chronic disease management, particularly benefiting users in nonindustrial nations.

Agamon is a healthcare intelligence platform that focuses on enhancing the management of radiology findings and follow-up recommendations. Utilizing advanced deep learning natural language processing technology, Agamon's platform automates the extraction of critical data from radiology reports, facilitating streamlined workflows, personalized communications, and monitoring of follow-up adherence. The platform effectively manages important healthcare programs, including Lung Cancer Screenings and the tracking of incidental findings such as pulmonary nodules and aortic aneurysms. By breaking down data silos and structuring unstructured data, Agamon provides physicians and researchers with valuable insights that are essential for advancing medical procedures, diagnostics, and treatment in the healthcare sector.

YonaLink operates a global network of over 30,000 medical centers, focusing on the collection and management of clinical trial data. The company offers a platform that streamlines the migration of clinical research data from electronic health records to electronic data capture systems, ensuring a secure and automated process. By enhancing trial efficiency and data quality, YonaLink alleviates the burden on medical center staff and broadens access to innovative patient care opportunities. Its solutions also aim to accelerate drug and medical device development while promoting patient diversity and enrollment in clinical trials, ultimately enabling healthcare providers and researchers to achieve faster and more accurate data capture.

GaitBetter is a health and wellness company based in Hefa, Israel, founded in 2017. It focuses on reducing fall risk and improving mobility for the senior adult population through innovative solutions. The company has developed a virtual reality walking platform that offers motor-cognitive therapy for gait rehabilitation and fall prevention. By leveraging artificial intelligence and gamification, GaitBetter's platform accelerates patient outcomes and provides personalized interventions that enhance cognitive functions related to safe walking. This approach aims to improve overall mobility and reduce the likelihood of falls among its clients.

AccuLine is a digital healthcare company focused on preventing heart attacks by offering innovative solutions for early detection of coronary artery disease (CAD). The company is developing CORA, a non-invasive examination technology that provides a smart, accurate, and user-friendly alternative to traditional stress tests. By streamlining the detection process, CORA enables healthcare providers to identify CAD more swiftly and cost-effectively, ultimately aiming to save millions of lives worldwide through timely intervention.

Olive Diagnostics has developed an innovative passive urine analysis sensor that can be mounted on any toilet, enabling continuous health monitoring through urinalysis. This sensor utilizes a combination of spectroscopy and artificial intelligence to analyze the urine stream and provide real-time health alerts to users. By uploading data to a cloud-based platform, Olive Diagnostics facilitates ongoing biomarker tracking for various health indicators such as hydration, alcohol levels, pregnancy, and ovulation. This technology not only empowers individuals to gain insights into their health and body functions but also offers pharmaceutical and clinical research organizations a reliable method to monitor drug compliance and usage. By making urine lab services accessible at home, Olive Diagnostics aims to enhance disease detection and chronic disease management, particularly benefiting users in nonindustrial nations.

AccuLine is a digital healthcare company focused on preventing heart attacks by offering innovative solutions for early detection of coronary artery disease (CAD). The company is developing CORA, a non-invasive examination technology that provides a smart, accurate, and user-friendly alternative to traditional stress tests. By streamlining the detection process, CORA enables healthcare providers to identify CAD more swiftly and cost-effectively, ultimately aiming to save millions of lives worldwide through timely intervention.

RespirAI Medical is focused on developing a wearable home monitoring platform designed for the management of chronic respiratory diseases. The company utilizes a passive sensor-based device that automatically uploads patient data to the cloud for analysis. Advanced algorithms powered by artificial intelligence assess deviations from established clinical baselines, enabling the early detection of exacerbations in respiratory health. This capability aims to enhance patient outcomes by allowing healthcare providers to respond promptly to changes in a patient's condition, ultimately improving the quality of life for individuals with chronic respiratory issues.

Symetrify is a company focused on providing digital health solutions aimed at enhancing musculoskeletal function. It develops non-invasive remedies to address functional issues within the neuromusculoskeletal system. Utilizing innovative technology, Symetrify's approach targets the underlying causes of pain and impairment, promoting improved structural motion in the human skeleton. The company's neuro-mechanical wearable training device is designed to assess, treat, and prevent spinal kinetic dysfunctions, particularly those related to chronic low back pain. By offering a non-invasive alternative, Symetrify enables patients to receive effective treatment without the need for painful therapies, ultimately fostering long-term improvements in health, performance, and injury prevention.

HappyDural has developed an AI-based system for personalized sedative drug administration management. The system enables the elimination of severe side effects of over-dosing and under-dosing throughout the entire injection period. This solution enables a significant reduction of the risk of life-threatening side effects and pain. The HappyDural solution is based on a sophisticated sensor array and a learning algorithm that enables an automated monitoring system to replace the manual procedure and provide personalized and immediate anesthesia. All of this is included in a simple, cost-effective system that is easily integrated into current equipment. HappyDural was established in the eHealth Ventures incubator.

Skelable is a robotics company that develops a medical device that provides rehabilitation for the patient. It helps therapists to treat their patients remotely. The company was founded in 2018 and headquartered in Tel Aviv, Israel

Ophthalmic Sciences is focused on addressing the critical need for effective glaucoma management through innovative technology. The company is developing the IOPerfect visor, a groundbreaking device designed to measure intraocular pressure (IOP) without direct contact with the eye or the use of air jets. This user-friendly and accurate system aims to assist approximately 150 million patients globally, offering a vital tool for monitoring and screening glaucoma, which is essential for preventing blindness. The device operates automatically and seamlessly uploads patient data to the cloud, ensuring timely access to crucial health information. With a team boasting over seventy years of combined experience and backing from leading glaucoma specialists, Ophthalmic Sciences has already secured $1.4 million in funding to achieve proof of concept and is actively seeking additional financing to advance toward market readiness in 2023, targeting a $7 billion market opportunity.

BrainWatch Tech is developing a real-time, continuous, automatic pupil reflex monitoring system for assessing the neurological status of unconscious patients in cases of traumatic brain injury, stroke, and brain surgery. The technology behind BrainWatch is an automatic monitoring system of the pupillary light reflex through closed eyes, using an optical system for image acquisition and AI for image and data analysis. BrainWatch's solution continuously monitors pupillary activity in unconscious patients through closed eyes, immediately alerting surgeons and staff to changes in the patient's condition. The system also enables pupil monitoring in real time during complex brain surgery. The product will look like a pair of virtual reality goggles, equipped with a camera lens and a light that will continuously monitor, measure, and record pupil size and reflex through the closed eyelids of patients with severe brain injury. The continuous monitoring will create a record of the patient's condition and response to treatment over time. BrainWatch Tech was established in the eHealth Ventures incubator, which fosters early-stage digital health start-ups.

Nervio is a digital health company that has created an innovative neuromonitoring solution designed to prevent avoidable paralysis and severe neurological complications during surgical procedures. This AI-powered system provides real-time alerts to clinicians regarding potential neurological complications in the operating room. By employing machine learning technologies and advanced clinical intelligence, Nervio's solution offers automated assessments and clinical recommendations, empowering surgeons to make informed decisions that minimize the risk of permanent nerve injuries. This approach enhances operational flexibility, addressing a critical need for innovation in surgical safety.

Olive Diagnostics has developed an innovative passive urine analysis sensor that can be mounted on any toilet, enabling continuous health monitoring through urinalysis. This sensor utilizes a combination of spectroscopy and artificial intelligence to analyze the urine stream and provide real-time health alerts to users. By uploading data to a cloud-based platform, Olive Diagnostics facilitates ongoing biomarker tracking for various health indicators such as hydration, alcohol levels, pregnancy, and ovulation. This technology not only empowers individuals to gain insights into their health and body functions but also offers pharmaceutical and clinical research organizations a reliable method to monitor drug compliance and usage. By making urine lab services accessible at home, Olive Diagnostics aims to enhance disease detection and chronic disease management, particularly benefiting users in nonindustrial nations.

Allerguard Ltd. is a Tel Aviv-based company founded in 2017 that specializes in the development of personal allergy detection systems. The company's innovative device is designed to analyze food by detecting allergen particles through the examination of vapors, rather than requiring physical samples, which may lead to missed allergens. This handheld sensor alerts users to the presence of allergens, including peanuts and tree nuts, by assessing food compounds and ensuring that the detected levels are within the safety limits established by international food standards. Allerguard provides a vital solution for individuals with food allergies, empowering them to make informed decisions about their meals prior to consumption.

Ophthalmic Sciences is focused on addressing the critical need for effective glaucoma management through innovative technology. The company is developing the IOPerfect visor, a groundbreaking device designed to measure intraocular pressure (IOP) without direct contact with the eye or the use of air jets. This user-friendly and accurate system aims to assist approximately 150 million patients globally, offering a vital tool for monitoring and screening glaucoma, which is essential for preventing blindness. The device operates automatically and seamlessly uploads patient data to the cloud, ensuring timely access to crucial health information. With a team boasting over seventy years of combined experience and backing from leading glaucoma specialists, Ophthalmic Sciences has already secured $1.4 million in funding to achieve proof of concept and is actively seeking additional financing to advance toward market readiness in 2023, targeting a $7 billion market opportunity.

EFA is engaged in developing innovative diagnostic tools aimed at making testing and diagnostics affordable and accessible globally. Their flagship product, RevDx (Revolutionary Diagnostics), is a mobile and portable device that utilizes advanced computerized microscopy to deliver automated blood tests and diagnostic capabilities. This handheld solution allows for easy operation through a simple finger prick, eliminating the need for laboratory conditions and specific preparations. RevDx enables real-time, on-the-spot diagnostics, providing essential information that can guide medical professionals in making informed decisions about treatments, such as the necessity of antibiotic use. By combining accurate diagnostics with data analytics, EFA's tools empower healthcare providers and researchers to enhance patient care and improve health outcomes.

TrainPain is a digital therapeutics company based in Tel Aviv-Yafo, Israel, specializing in innovative treatments for chronic neuropathic pain. The company's platform combines wearable hardware with personalized sensory training games designed to rehabilitate dysfunctional sensory processing and reduce pain-related hypersensitivity in the nervous system. TrainPain's low-cost, home-based solution includes a proprietary tactile stimulation device and engaging mobile video games that assess and treat pain-related neuroplasticity. Available in both virtual reality and smartphone formats, the platform aims to improve the mental and emotional well-being of individuals suffering from neuropathic pain and fibromyalgia by providing interactive experiences that not only distract from pain but also address its underlying causes.

SensoGenic, Inc. develops innovative diagnostic biosensors specifically designed to detect food allergens. Founded in 2016 and based in Ness Ziona, Israel, the company offers portable, handheld analyzers that connect to a mobile application, allowing users to identify allergens without physical contact. This technology provides critical information for individuals with food allergies, enabling them to dine out safely and avoid allergic reactions. SensoGenic emphasizes understanding user needs to enhance the functionality and usability of its products, positioning itself as a leader in allergen detection solutions.

Allerguard Ltd. is a Tel Aviv-based company founded in 2017 that specializes in the development of personal allergy detection systems. The company's innovative device is designed to analyze food by detecting allergen particles through the examination of vapors, rather than requiring physical samples, which may lead to missed allergens. This handheld sensor alerts users to the presence of allergens, including peanuts and tree nuts, by assessing food compounds and ensuring that the detected levels are within the safety limits established by international food standards. Allerguard provides a vital solution for individuals with food allergies, empowering them to make informed decisions about their meals prior to consumption.

DermaDetect is a developer of an AI-driven digital dermatology platform designed to diagnose and manage skin, hair, and nail conditions. The platform allows patients to conduct self-assessments and analyze non-pigmented skin lesions and acute diseases from anywhere, facilitating remote diagnosis. By automatically detecting skin issues and recommending treatments, DermaDetect enhances access to dermatological care. Additionally, it connects patients with nearby physicians for further assistance, making it easier for individuals to receive timely and effective care for skin disorders from the comfort of their homes.

Tiktalk To Me owns and operates a digital health company intended to offer a platform for speech therapy. Its platform functions as a virtual speech therapist, guiding patients through proven and widely accepted training protocols using online games supervised by the patient's personal speech therapist and combines gaming with speech- and voice-recognition technology, enabling speech-language pathologists to shorten the treatment cycle and save substantial time and money for the patients.